RESEARCH ARTICLE

5-aminolaevulinic acid (5-ALA) accumulates in GIST-T1 cells and photodynamic diagnosis using 5-ALA identifies gastrointestinal stromal tumors (GISTs) in xenograft tumor models

Makiko Sasaki, Mamoru Tanaka , Hiroshi Ichikawa, Taketo Suzuki, Hirotada Nishie, Keiji Ozeki, Takaya Shimura, Eiji Kubota, Satoshi Tanida, Hiromi Kataoka

Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Science, Nagoya, Aichi, Japan

* mtanaka@med.nagoya-cu.ac.jp

Abstract

Gastrointestinal stromal tumor (GIST) diagnosis using conventional gastrointestinal endoscopy is difficult because such malignancies cannot be distinguished from other types of submucosal tumors. Photodynamic diagnosis (PDD) is based on the preferential uptake of photosensitizers by tumor tissues and its detection by fluorescence emission upon laser excitation. In this study, we investigated whether PDD using 5-aminolaevulinic acid (5-ALA), a standard photosensitizer used worldwide, could be used for GIST diagnosis. 5-ALA is metabolized to endogenous fluorescent protoporphyrin IX (PpIX). We examined the accumulation of PpIX in GIST-T1 cells using flow cytometry and immunofluorescent staining. Furthermore, we established GIST-T1 xenograft mouse models and examined PpIX accumulation in the resultant tumors. PpIX accumulated in GIST-T1 cells and was localized mainly to lysosomes. PpIX accumulation was also observed in murine xenograft tumors. Moreover, tumor and normal tissues could be distinctly identified by relative PpIX fluorescence. Thus, our results demonstrated that PDD with 5-ALA has substantial clinical potential for GIST diagnosis.

Introduction

GISTs are the most common submucosal tumors (SMTs) of the gastrointestinal tract observed in clinical practice, with a population prevalence of 14–20 cases per million [1, 2]. GISTs can occur anywhere in the gastrointestinal system, with 50%–60% located in the stomach, 30%–35% in the small intestine, 5% in the colon and rectum, and < 1% in the esophagus [3]. If the GIST is localized, the 5-year survival rate is 94%; when spread locally, this becomes 82%, and if the GIST exhibits distant metastasis at the time of diagnosis, the 5-year survival rate is 52% [4]. SMTs are derived from mesenchymal cells, and because of this, SMTs are generally enveloped by normal mucosa, which makes it difficult to differentially diagnose GISTs from other types of SMTs using conventional endoscopy. At present, endoscopic ultrasound-guided fine needle
aspiration (EUS-FNA) has been developed, which enables pathological diagnosis of SMTs, including GISTs [5]. However, such diagnosis requires advanced technical skills that are limited to expert endoscopists. Additionally, performing EUS-FNA targeting small SMTs < 2 cm in diameter is especially difficult. GISTs occur anywhere along the gastrointestinal system and have malignant potential. Moreover, no effective treatment strategies, except for surgical resection, are currently available for GISTs. Hence, the present situation of diagnosis and treatment of GISTs is challenging.

Photodynamic diagnosis (PDD), wherein tumor and normal tissues are identified by characteristically different fluorescent wavelengths, has been demonstrated to be an effective diagnostic technique for certain types of tumors, and is widely used in clinical applications [6]. PDD is based on the preferential uptake of photosensitizers by tumor tissues and its detection by fluorescence emission upon laser excitation to distinguish tumors from normal tissue. 5-aminolevulinic acid (5-ALA), a standard photosensitizer used in PDD, is a naturally occurring amino acid that has been widely used in clinical applications owing to its specificity toward some tumors and its demonstrated safety [7–11]. In Japan, 5-ALA PDD has been approved for health insurance coverage in cases of brain tumors (in particular, malignant glioma) and bladder tumors. 5-ALA is synthesized from glycine and succinyl-CoA by the enzyme 5-ALA synthase, which is dependent on vitamin B6 in mitochondria. 5-ALA is not itself fluorescent; however, it is a metabolic precursor in the heme biosynthetic pathway, and is further metabolized into endogenous fluorescent protoporphyrin IX (PpIX) (Fig 1) [12, 13]. PpIX emits red fluorescence between 600 and 740 nm when irradiated with 375–445 nm laser illumination [14–16]. This conversion of 5-ALA to its active compound PpIX in tissues has been used for PDD in many clinical applications, particularly because it substantially accumulates in tumor cells rather than in normal cells [7–9, 17, 18]. The reasons why PpIX accumulates much more in cancer cells than in normal cells are unclear, but two major hypotheses have been proposed: (1) PpIX accumulates in cancer cells because of a decrease in ferrochelatase activity; (2) 5-ALA has a high affinity for cancer cells [12, 19, 20].

To the best of our knowledge, many reports have been published regarding the accumulation of PpIX in different types of human cancer cell lines [21–36], but PDD of GISTs using 5-ALA has not yet been reported. In a similar study concerning PDD, Fujimoto et al. reported that molecular fluorescent imaging using a near-infrared (NIR) photosensitizer conjugated anti c-kit antibody was able to detect GISTs, making NIR irradiation a very efficacious therapeutic (a newly coined term combining “therapeutics” and “diagnosis”) technology for GIST [37]. We previously demonstrated the antitumor effects of photodynamic therapy (PDT) in GIST using glucose-conjugated chlorin [38, 39]; however, PDD of GIST using 5-ALA has not been reported to date. Therefore, we investigated whether PDD with 5-ALA could be used for GIST detection as this could have therapeutic potential in combination with glucose-conjugated chlorin. Here, we show that PDD with 5-ALA has clinical potential for GIST diagnosis.

Materials and methods

Ethics statement

This study was carried out in strict accordance with the recommendations and guidelines of the Nagoya City University for Animal Experiments. The protocol was approved by the Committee of Laboratory Animal Facility at Nagoya City University for Experimental Animal Science under permit number 19–024. All experiments involving animals were performed under anesthesia, and all efforts were made to minimize suffering.
Photosensitizer

5-ALA was obtained from Cosmo Bio Co., Ltd. (Tokyo, Japan) and dissolved in 0.9% normal saline at a concentration of 720 mmol/L. For the in vitro studies, 5-ALA was diluted in cell culture medium.

Cell line and culture methods

The human GIST cell line GIST-T1 (code number: GIST01, Cosmo Bio Co.) was purchased in 2014. In addition to negative test results for mycoplasma contamination, cell line authentication and characterization were performed by Cosmo Bio Co. The International Council for Laboratory Animal Science (ICLAS) Monitoring Center, Central Institute for Experimental Animals, tested the cell line for the presence of viruses, with negative results. All experiments using cells in this study were performed for less than 20 passages. GIST-T1 cells were cultured in high glucose (4500 mg/L) Dulbecco's modified Eagle's medium (DMEM, Wako Pure Chemical Industries, Osaka, Japan) supplemented with 10% heat-inactivated fetal bovine
serum (Biosera, Nuaille, France) and 1% penicillin-streptomycin-amphotericin B suspension (Wako Pure Chemical Industries) under 5% CO$_2$ and at 37˚C.

**Flow cytometric analysis**

GIST-T1 cells were resuspended in 6-cm culture dishes at a density of $1 \times 10^6$ cells/well in culture medium and incubated at 37˚C with 5% CO$_2$ for 24 h. Following this, the medium was replaced with fresh medium supplemented with 0.89 mmol/L 5-ALA added to the dishes for 0, 15, 30, and 60 min to evaluate the accumulation of photosensitizer in cells. After washing the cells with phosphate-buffered saline (PBS) three times, cells were removed from the culture dish after trypsin-EDTA treatment for analysis using a flow cytometer with excitation at 405 nm and emission at 680 nm. All flow cytometric examinations were performed on a FACS-Canto II (BD Biosciences, San Jose, CA, USA), and 10,000 events were counted and analyzed using FlowJo software (BD Biosciences).

**Subcellular localization of 5-ALA**

GIST-T1 cells were seeded into 8-well chamber plates at a density of $1 \times 10^4$ cells/well and incubated at 37˚C with 5% CO$_2$ for 24 h. Subsequently, 5-ALA was added to the culture media to a final concentration of 8 mmol/L, and the cells were further incubated for 2 h for staining with organelle-specific fluorescent probes. Lysosomes were stained with 0.1 μmol/L Lyso-Tracker Green (Thermo Fisher Scientific, Waltham, MA, USA) at 37˚C with 5% CO$_2$ for 30 min, mitochondria with 0.1 μmol/L MitoTracker Green FM (Thermo Fisher Scientific) at 37˚C with 5% CO$_2$ for 10 min, Golgi with 5 μmol/L NBD C6-ceramide (Thermo Fisher Scientific) at 4˚C on ice for 30 min, and endoplasmic reticulum (ER) with 0.1 μmol/L ER-Tracker Green (Thermo Fisher Scientific) at 37˚C with 5% CO$_2$ for 30 min. After incubation under each condition, the culture media were replaced with fresh media to remove free dyes. Stained cells were directly examined for accumulation in mitochondria, followed by fixation with 4% paraformaldehyde for accumulation identification in lysosomes, Golgi, and ER. Intracellular localization was visualized using a confocal laser microscope (FV3000, Olympus, Tokyo, Japan) and cellSens imaging software (Olympus). Band-pass emission filters of 500–540 nm and 488 nm for organelle-specific fluorescent probes, and 570–670 nm and 561 nm for PpIX were used. We measured the fluorescence intensity profiles. Arrows in micrographs showed the direction of scanning, and the histograms showed the strength of the fluorescent signals for evaluation of the peaks and trends of each luminescence. Co-localization was measured the whole each image, and the average values were calculated. Fluorescence intensity profiles were examined via confocal imaging, and quantitative analysis was performed using cellSens imaging software. Data from three independent experiments are presented as means ± standard deviation (SD). Statistical significance was determined by Tukey’s multiple comparison test and was set at $P < 0.01$.

**Animal models**

Our experiments used murine animal models involving pathogen-free female nude mice (BALB/c Slc-nu/nu), 6–8 weeks of age, with a body weight of 18–22 g, which were purchased from Shizuoka Laboratory Animal Center (Shizuoka, Japan). Fifty mice were used in this study, including in preliminary experiments. Mice were kept under pathogen-free conditions under controlled temperature and humidity, 12 h light and 12 h dark cycle conditions, and fed a sterilized pellet diet with water *ad libitum*. Before commencing any intervention, all mice were acclimatized for at least 2 weeks in our animal facility. The health of the mice was monitored, and tumor sizes were measured every 2 days. Tumor volumes were calculated using the
following formula: volume (mm$^3$) = length (mm) × width (mm) × height (mm) × 0.5. Animals found to be unhealthy (loss of ambulation, appetite, or weight) were promptly planned to be euthanized. In addition, any mouse with a tumor size of 1000 mm$^3$ was designated to be euthanized. None of the mice were found to be unhealthy or died throughout this study. Cervical dislocation was used for euthanasia. Mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg) reconstituted in physiological saline solution.

Xenograft models of flank tumors were established by subcutaneously implanting $3.4 \times 10^7$ GIST-T1 cells in 200 μL of medium and equivalent amounts of Matrigel (Corning, New York, USA) under the flanks of mice. Xenograft models of peritoneal dissemination were established by implanting $2.5 \times 10^7$ GIST-T1 cells in 100 μL of medium into the abdominal cavity. PDD was performed after tumor size reached 100–300 mm$^3$ in flank tumor models, and all mice were euthanized at the time of PDD.

In vivo PDD

In vivo PDD was started when tumor sizes reached 100–300 mm$^3$ in flank tumor models 5 weeks after the injection of tumor cells. We considered three groups (n = 3) of flank tumor models as follows: a dose of 300 mg/kg 5-ALA was injected and PDD conducted after 4 h, 300 mg/kg and 7 h, and 600 mg/kg and 4 h. Peritoneal seeding models were intended to form peritoneal dissemination nodules around the same time as the flank tumor was established, and a dose of 300 mg/kg 5-ALA was injected via the tail vein. Mice were sacrificed after 4 and 7 h, in accordance with our institutional guidelines, followed by tumor extraction. Tumors were exposed to white light and LED illumination (420 nm). Images were captured using a high-resolution camera equipped with an optical filter (cut-off 470 nm, long band pass filter VIS 470 nm, (Asahi Spectra, Tokyo, Japan)).

Spectrophotometric analysis

We examined the accumulation of photosensitizers in murine xenograft tumors using a semiconductor laser with a VLD-M1 spectrometer (M&L, Tokyo, Japan) and its accessory software (BW-Spec V3.24; B&W TEK, Inc., Newark, DE, USA). The spectrometer emitted laser light with a peak wavelength of 405 ± 1 nm and a light output of 140 mW. We used the manufacturer’s software to analyze spectral waveforms. The relative fluorescence intensity ratio in tumor and normal tissues was calculated by dividing the relative fluorescence intensity of PpIX (635 nm) by that of autofluorescence (505 nm) [38–41]. Following injection of 300 mg/kg 5-ALA in the xenograft flank tumor model animals after 4 h, the data—in view of the results of in vivo PDD—was obtained when conditions were optimal. Data from three independent experiments are presented as means ± standard deviation (SD). Significance was calculated using Student’s t-test.

Statistical analysis

Descriptive statistics and samples were analyzed using Prism software (v.6.0; GraphPad Software, Inc., San Diego, CA, USA). Statistical significance was determined by Tukey’s multiple comparison test for quantitative analysis of subcellular localization of PpIX. Student’s t-test was performed for spectrometric analyses.

Results

PpIX accumulated in GIST-T1 cells

We examined the uptake of PpIX by GIST-T1 cells in vitro. We incubated cells with 0.89 mmol/L 5-ALA for 0, 15, 30, and 60 min. Then, we measured the intensity of the characteristic
red fluorescence at the single-cell level using fluorescence-activated cell sorting (FACS). The accumulation of PpIX in GIST-T1 cells increased in a time-dependent manner (Fig 2).

**PpIX in GIST-T1 cells accumulates mainly in lysosomes**

Accumulation and subcellular localization of PpIX were investigated using confocal microscopy employing fluorescent probes to specifically label intracellular organelles. Cells were loaded with 5-ALA and incubated with each organelle-specific fluorescent probe (MitoTracker Green, LysoTracker Green, NBD C6 ceramide Green, or ERTracker Green) to label mitochondria, lysosomes, Golgi, and ER, respectively. The corresponding detection of PpIX with LysoTracker indicated accumulation in lysosomes (Fig 3A). The fluorescence intensity profiles for PpIX detection exhibited a tendency to correlate with the lysosome tracking marker (Fig 3B), and quantitative analysis revealed that the percentage of subcellular localization of PpIX was significantly greater in lysosomes (P < 0.01).

**PDD with 5-ALA distinctly identifies GIST in vivo**

We tested photosensitizer fluorescence in xenograft tumor mouse models. After the implanted tumors grew to 100–300 mm³ in flank tumor models, 5-ALA was administered to mice, and all mice were euthanized after several hours. The extracted tumors were exposed to white light and LED irradiation. Tumors treated with 5-ALA clearly emitted red fluorescence under 420 nm LED excitation. In the flank tumor models, the highest level of fluorescence was measured at a dose of 300 mg/kg 5-ALA for 4 h. In peritoneal seeding models, we could not identify...
peritoneal dissemination through the skin via LED light, but the extracted tumors emitted strong fluorescence (Fig 4).

PpIX accumulation in xenograft tumors

We examined PpIX accumulation in xenograft tumors established by subcutaneous or intra-peritoneal implantation of GIST-T1 cells. After intravenous injection (via the tail vein) of 5-ALA, the spectral waveforms of xenograft tumors were measured using a spectrometer (VLD-M1). Spectral waveform analysis revealed that a peak of fluorescence emission was observed at 635 nm, corresponding to PpIX (Fig 5). Generally, autofluorescence levels were centered around 505 nm. We then examined relative fluorescence intensity ratios (at 635/505 nm) of photosensitizers in tumors and normal tissues surrounding the tumors using a spectrometer. Data were obtained from three independent experiments in each group. The increase in the ratio demonstrated the significance of the difference in accumulation between normal skin and GIST ($P < 0.05$) (Table 1).

Discussion

In this study, we observed excellent in vitro and in vivo accumulation and fluorescence using 5-ALA in GISTs. 5-ALA is a standard photosensitizer used worldwide for PDD [42].
Therefore, we investigated the potential of PDD in GIST by examining the *in vitro* and *in vivo* accumulation of PpIX, which is a metabolite of 5-ALA.

We observed that *in vitro* accumulation of PpIX was mainly localized to tumor cell lysosomes, which have been proposed to be critical for photosensitizer action [43]. Hamblin et al. reported that photosensitizers principally accumulate in endosomes and lysosomes, unless they are metabolized and released from lysosomes [44]. In several cancer cell types, the synthesis of PpIX is typically promoted by an increase in the activity of the β-transporter and porphobilinogen deaminase, whereas the metabolizing pathway of PpIX is inhibited by an increase in

![Graph showing fluorescence emission at 505 nm and 635 nm](https://doi.org/10.1371/journal.pone.0249650.g005)

**Fig 5. 5-ALA accumulation in GIST in vivo.** Flank tumor models were administered with 300 mg/kg 5-ALA via the tail vein. Four hours after 5-ALA administration, the spectral waveforms of normal skin tissue (blue line) and GIST (red line) were examined using a VLD-M1 spectrometer. A peak of fluorescence emission was observed at 635 nm, corresponding to PpIX.

| Emission at 505 nm  | Normal skin  | GIST  | P-value |
|---------------------|--------------|-------|---------|
| 1960 ± 260          | 2080 ± 200   |       | 0.353   |
| Emission at 635 nm  | 2210 ± 960   | 7110 ± 600 | 0.011 < 0.05 |
| 635 nm / 505 nm ratio | 1.09 ± 0.34 | 3.43 ± 0.05 | 0.012 < 0.05 |

**Table 1. Autofluorescence in normal skin tissues and fluorescence intensity using 5-ALA in GIST.**

Autofluorescence in normal skin tissues and fluorescence intensity following treatment with 5-ALA in GIST and relative fluorescence intensities. The conditions were as described in the legend of **Fig 5**. These data were obtained from xenograft flank tumor models injected with 300 mg/kg 5-ALA after 4 h.

[https://doi.org/10.1371/journal.pone.0249650.t001](https://doi.org/10.1371/journal.pone.0249650.t001)
the activity of the transferrin receptor and a decrease in the activity of ferrochelatase (Fig 1). Moreover, the requirement for heme is low in cancer cells because such cells depend on glycolytic energy production (the so-called Warburg effect) [45]. As a result, PpIX accumulates in cancer cells [46, 47]. These reports confirm our result that PpIX accumulation in GIST-T1 cells was mainly localized to lysosomes. We previously synthesized and reported PDD using oligosaccharide-conjugated chlorin (O-chlorin) [48]. In our previous study, we confirmed that O-chlorin accumulated in MKN45 (a human gastric cancer cell line), and was mainly localized to lysosomes. In addition, another photosensitizer, hypericin, is reported to localize to the ER and lysosomes in HeLa cells [49]. Based on these reports, we consider that many photosensitizers used in the field of PDD tend to accumulate in lysosomes. On the contrary, certain photosensitizers used for PDT accumulate in various subcellular compartments, such as photosensitizer localization in mitochondria, lysosomes, and Golgi apparatus [50], and photosensitizer I, which is a novel photosensitizer reported by Peng-Xi Li, accumulates in the mitochondria and ER of HeLa cells [51]. A recent study showed that the same photosensitizers exhibit different localizations in various cell lines [52]. Therefore, identification of photosensitizer localization requires further consideration.

Fluorescence emission was observed in murine xenograft tumors treated with 5-ALA. However, this emission was dependent on the time elapsed following 5-ALA administration, as well as its concentration. Higher doses of photosensitizer rendered the visual distinction of fluorescence emitted by the tumor and normal tissue difficult, thereby leading to incorrect PDD of SMTs. Similarly, clear fluorescence was observed only within a specific timeframe following 5-ALA administration. In previous studies, the optimal time to evaluate the fluorescence of 5-ALA in PDD was indicated to be 1–4 h [51, 53]. Although these studies involved different cell lines and routes of drug administration, they do not contradict our results.

Extensive research has been conducted concerning malignancies of the digestive tract, including gastric, esophageal, and colon cancers, among others. In Japan, peritoneal metastasis of gastric cancer has been a major area of focus for the development of pharmaceutical agents. Laser-based photodynamic endoscopic diagnosis of early gastric and colorectal cancers using 5-ALA has been reported, although the issue of fluorescent intensity differences among histopathological types has not yet been resolved [15, 54]. However, a recent study suggested that gastric cancer cell lines expressing high levels of ATP-binding cassette transporters tend to exhibit low levels of 5-ALA staining [55]. We previously demonstrated the efficacy of PDT with a novel glucose-conjugated photosensitizer, glycocon-conjugated chlorin (5, 10, 15, 20-tetrakis [4-[[β-D-glucopyranosylthio]-2, 3, 5, 6-tetrafluorophenyl]-2, 3, 5-methano[N-methyl] iminomethano] chlorin, H2TFPC-SGlc) in GIST, both in vitro and in vivo [38]. Nevertheless, the GIST diagnostic approach presents a greater potential for improvement compared to conventional methods.

In summary, the accumulation of PpIX in GIST-T1 cells, specifically in lysosomes, as well as the photodynamic detection of PpIX in murine xenograft models, demonstrates a strong potential for PDD and clinical applications in the future.

**Supporting information**

**S1 Fig. Fluorescent imaging of murine GIST xenograft models.** Images were acquired using a high-resolution camera equipped with an optical filter. Each image was photographed under white (left side) and LED light illumination (right side). The remaining two mice of each group, except for those shown in Fig 4, are shown in this figure. Mice used during preliminary experiments under other conditions (600 mg/kg 5-ALA for 7 h and control) are also included. (TIF)
Acknowledgments
We thank Yoko Matsuoka, Suzuka Asai and Yukimi Ito (Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan) for their technical assistance.

Author Contributions
Conceptualization: Makiko Sasaki.
Data curation: Makiko Sasaki, Mamoru Tanaka, Taketo Suzuki, Hirotada Nishie.
Funding acquisition: Mamoru Tanaka.
Investigation: Makiko Sasaki, Hiroshi Ichikawa, Taketo Suzuki, Hirotada Nishie.
Methodology: Makiko Sasaki.
Project administration: Makiko Sasaki, Mamoru Tanaka.
Software: Hiroshi Ichikawa, Taketo Suzuki.
Supervision: Mamoru Tanaka, Hiromi Kataoka.
Validation: Keiji Ozeki, Takaya Shimura, Eiji Kubota, Satoshi Tanida.
Writing – original draft: Makiko Sasaki.
Writing – review & editing: Mamoru Tanaka, Hiromi Kataoka.

References
1. Hwang JH, Kimmey MB. The incidental upper gastrointestinal subepithelial mass. Gastroenterology. 2004; 126(1):301–7. Epub 2003/12/31. https://doi.org/10.1053/j.gastro.2003.11.040 PMID: 14699508.
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013; 382 (9896):973–83. Epub 2013/04/30. https://doi.org/10.1016/S0140-6736(13)60106-3 PMID: 23623056.
3. Joensuu H, Vehtari A, Rihimäki J, Nishida T, Steigen SE, Brabec P, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012; 13(3):265–74. Epub 2011/12/14. https://doi.org/10.1016/S1470-2045(11)70299-6 PMID: 22153892.
4. Ahmed M. Recent advances in the management of gastrointestinal stromal tumour. World J Clin Cases. 2020; 8(15):3142–55. Epub 2020/09/03. https://doi.org/10.12998/wjcc.v8.i15.3142 PMID: 32874969; PubMed Central PMCID: PMC7441252.
5. Akahoshi K, Oya M, Koga T, Shiraishi Y. Current clinical management of gastrointestinal stromal tumor. World J Gastroenterol. 2018; 24(26):2806–17. Epub 2018/07/19. https://doi.org/10.3748/wjg.v24.i26.2806 PMID: 30018476; PubMed Central PMCID: PMC6048423.
6. Crow P, Stone N, Kendall CA, Persad RA, Wright MP. Optical diagnostics in urology: current applications and future prospects. BJU Int. 2003; 92(4):400–7. Epub 2003/08/22. https://doi.org/10.1046/j.1464-410x.2003.04368.x PMID: 12930429.
7. Stummer W, Pichimeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006; 7(5):392–401. Epub 2006/05/02. https://doi.org/10.1016/S1470-2045(06)70665-9 PMID: 16648043.
8. Motoori M, Yano M, Tanaka K, Kishi K, Takahashi H, Inoue M, et al. Intraoperative photodynamic diagnosis of lymph node metastasis in esophageal cancer patients using 5-aminolevulinic acid. Oncol Lett. 2015; 10(5):3035–9. Epub 2016/01/02. https://doi.org/10.3892/ol.2015.3685 PMID: 26722285; PubMed Central PMCID: PMC4665204.
9. Denzinger S, Burger M, Walter B, Kneuechel R, Roessler W, Wieland WF, et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology. 2007; 69(4):675–9. Epub 2007/04/21. https://doi.org/10.1016/j.urology.2006.12.023 PMID: 17445650.
10. Namikawa T, Yatabe T, Inoue K, Shin T, Hanazaki K. Clinical applications of 5-aminolevulinic acid-mediated fluorescence for gastric cancer. World J Gastroenterol. 2015; 21(29):8769–75. Epub 2015/
Regula J, MacRobert AJ, Gorchein A, Buonaccorsi GA, Thorpe SM, Spencer GM, et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5-aminolevulinic acid induced protoporphyrin IX—a pilot study. Gut. 1995; 36(1):67–75. Epub 1995/01/01. https://doi.org/10.1136/gut.36.1.67 PMID: 7890239; PubMed Central PMCID: PMC1382355.

11. Yang X, Palasubramian P, Chen B. Aminolevulinic Acid-Based Tumor Detection and Therapy: Molecular Mechanisms and Strategies for Enhancement. Int J Mol Sci. 2015; 16(10):25865–80. Epub 2015/10/31. https://doi.org/10.3390/ijms161025865 PMID: 26516850; PubMed Central PMCID: PMC4632830.

12. Inoue Y, Tanaka R, Komeda K, Hirokawa F, Hayashi M, Uchiyama K. Fluorescence detection of malignant liver tumors using 5-aminolevulinic acid-mediated photodynamic diagnosis: principles, technique, and clinical experience. World J Surg. 2014; 38(7):1786–94. Epub 2014/02/05. https://doi.org/10.1007/s00268-014-2463-9 PMID: 24493071.

13. Teng L, Nakada M, Zhao SG, Endo Y, Furuyama N, Nambu E, et al. Silencing of ferrochelatase enhances 5-aminolevulinic acid-based fluorescence and photodynamic therapy efficacy. Br J Cancer. 2011; 104(5):798–807. Epub 2011/02/10. https://doi.org/10.1038/bjc.2011.12 PMID: 21304523; PubMed Central PMCID: PMC3048207.

14. Inoue Y, Tanaka R, Komeda K, Hirokawa F, Hayashi M, Uchiyama K. Fluorescence detection of malignant liver tumors using 5-aminolevulinic acid-mediated photodynamic diagnosis: principles, technique, and clinical experience. World J Surg. 2014; 38(7):1786–94. Epub 2014/02/05. https://doi.org/10.1007/s00268-014-2463-9 PMID: 24493071.

15. Kurumi H, Kanda T, Kawaguchi K, Yashima K, Koda H, Ogihara K, et al. Protoporphyrinogen oxidase is involved in the fluorescence intensity of 5-aminolevulinic acid-mediated laser-based photodynamic endoscopic diagnosis for early gastric cancer. Photodiagnosis Photodyn Ther. 2018; 22:79–85. Epub 2018/02/10. https://doi.org/10.1016/j.pdpt.2018.02.005 PMID: 29425880.

16. Inoue K. 5-Aminolevulinic acid-mediated photodynamic therapy for bladder cancer. Int J Urol. 2017; 24(2):97–101. Epub 2017/02/14. https://doi.org/10.1111/iju.13291 PMID: 28191719.

17. Kondo Y, Murayama Y, Konishi H, Morimura R, Komatsu S, Shiozaki A, et al. Fluorescent detection of peritoneal metastasis in human colorectal cancer using 5-aminolevulinic acid. Int J Oncol. 2014; 45(1):1–6. Epub 2014/05/14. https://doi.org/10.3892/ijo.2014.2417 PMID: 24821506; PubMed Central PMCID: PMC4079156.

18. Hinnen P, de Rooij FW, van Velthuysen ML, Edixhoven A, van Hillegersberg R, Tilanus HW, et al. Biochemical basis of 5-aminolevulinic acid-induced protoporphyrin IX accumulation: a study in patients with (pre)malignant lesions of the oesophagus. Br J Cancer. 1998; 78(5):679–82. Epub 1998/09/23. https://doi.org/10.1038/bjc.1998.559 PMID: 9744510; PubMed Central PMCID: PMC2063052.

19. Rodriguez L, Battle A, Di Venosa G, MacRobert AJ, Battah S, Daniel H, et al. Study of the mechanisms of uptake of 5-aminolevulinic acid derivatives by PEPT1 and PEPT2 transporters as a tool to improve photodynamic therapy of tumours. Int J Biochem Cell Biol. 2006; 38(9):1530–9. Epub 2006/04/25. https://doi.org/10.1016/j.biocel.2006.03.002 PMID: 16632403.

20. Yonemura Y, Endo Y, Canbay E, Liu Y, Ishibashi H, Mizumoto A, et al. Photodynamic Detection of Peritoneal Metastases Using 5-Aminolevulinic Acid (ALA). Cancers (Basel). 2017; 9(3). Epub 2017/03/04. https://doi.org/10.3390/cancers9030023 PMID: 28257041; PubMed Central PMCID: PMC5366818.

21. El-Khatib M, Tepe C, Senger B, Diboué-Adjei M, Riemenschneider MJ, Stummer W, et al. Aminolevulinic acid-mediated photodynamic therapy of human meningioma: an in vitro study on primary cell lines. Int J Mol Sci. 2015; 16(5):9936–48. Epub 2015/05/06. https://doi.org/10.3390/ijms16059936 PMID: 25941934; PubMed Central PMCID: PMC4463626.

22. Kim CH, Chung CW, Choi KH, Yoo JJ, Kim DH, Jeong YI, et al. Effect of 5-aminolevulinic acid-based photodynamic therapy via reactive oxygen species in human cholangiocarcinoma cells. Int J Nanomedicine. 2011; 6:1357–63. Epub 2011/07/16. https://doi.org/10.2147/IJN.S21395 PMID: 21760730; PubMed Central PMCID: PMC3133526.

23. Hino H, Murayama Y, Nakanishi M, Inoue K, Nakajima M, Otsuji E. 5-Aminolevulinic acid-mediated photodynamic therapy using light-emitting diodes of different wavelengths in a mouse model of peritoneally disseminated gastric cancer. J Surg Res. 2013; 185(1):119–26. Epub 2013/06/12. https://doi.org/10.1016/j.jss.2013.05.048 PMID: 23746762.

24. Mohammad Z, Sazgamia A, Rajabi O, Soudmand S, Esmaily H, Sadeghi HR. An in vitro study on the photosensitivitstv of 5-aminolevulinic acid conjugated gold nanoparticles. Photodiagnosis Photodyn Ther. 2013; 10(4):382–8. Epub 2013/11/29. https://doi.org/10.1016/j.pdpt.2013.03.010 PMID: 24284090.

25. Sailer R, Strauss WS, Wagner M, Emmert H, Schneckenburger H. Relation between intracellular location and photodynamic efficacy of 5-aminolevulinic acid-induced protoporphyrin IX in vitro. Comparison between human glioblastoma cells and other cancer cell lines. Photochem Photobiol Sci. 2007; 6(2):145–51. Epub 2007/02/06. https://doi.org/10.1039/b611715e PMID: 17277837.

26. Oghani Y, Miyata Y, Miyagi T, Gotoh S, Ohta T, Kataoka T, et al. Roles of porphyrin and iron metabolism in the 5-aminolevulinic acid (ALA)-induced accumulation of protoporphyrin and photodamage of...
tumor cells. Photochem Photobiol. 2011; 87(5):1138–45. Epub 2011/06/15. https://doi.org/10.1111/j.1751-1097.2011.00950.x PMID: 21668870.

27. Zakaria S, Gamal-Eldeen AM, El-Daly SM, Saleh S. Synergistic apoptotic effect of Doxil® and aminolevulinic acid-based photodynamic therapy on human breast adenocarcinoma cells. Photodiagnostics Photodyn Ther. 2014; 11(2):227–38. Epub 2014/03/19. https://doi.org/10.1016/j.pdpdt.2014.03.001 PMID: 24632331.

28. Hirano T, Hagiya Y, Fukuhara H, Inoue K, Shuin T, Matsumoto K, et al. Improvement of aminolevulinic acid (ALA)-mediated photodynamic diagnosis using n-propyl gallate. Photodiagnostics Photodyn Ther. 2013; 10(1):28–32. Epub 2013/03/08. https://doi.org/10.1016/j.pdpdt.2012.06.002 PMID: 23465369.

29. Kobuchi H, Moriya K, Ogino T, Fujita H, Inoue K, Shuin T, et al. Mitochondrial localization of ABC transporter ABCG2 and its function in 5-aminolevulinic acid-mediated protoporphyrin IX accumulation. PLoS One. 2012; 7(11):e50082. Epub 2012/11/29. https://doi.org/10.1371/journal.pone.0050082 PMID: 23189181; PubMed Central PMCID: PMC3506543.

30. Datta SN, Loh CS, MacRobert AJ, Whatley SD, Matthews PN. Quantitative studies of the kinetics of 5-aminolevulinic acid-induced fluorescence in bladder transitional cell carcinoma. Br J Cancer. 1998; 78(6):1113–8. Epub 1998/10/29. https://doi.org/10.1038/bjc.1998.637 PMID: 9792160; PubMed Central PMCID: PMC2063156.

31. Yamamoto M, Fujita H, Katase N, Inoue K, Nagatsuka H, Utsumi K, et al. Improvement of the efficacy of 5-aminolevulinic acid-mediated photodynamic treatment in human oral squamous cell carcinoma HSC-4. Acta Med Okayama. 2013; 67(3):153–64. Epub 2013/06/28. https://doi.org/10.18926/AMO/50408 PMID: 23894139.

32. Suzuki C, Tsuji AB, Kato K, Kikuchi T, Sudo H, Okada M, et al. Preclinical characterization of 5-aminolevulinic acid (5-ALA) and its derivatives for photodynamic therapy of human breast adenocarcinoma cells. J Photochem Photobiol B. 2012; 113(1):12–7. Epub 2012/03/01. https://doi.org/10.1016/j.jphotobiol.2012.03.009 PMID: 22394048.

33. Chen X, Zhao P, Chen F, Li L, Luo R. Effect and mechanism of 5-aminolevulinic acid-mediated photodynamic therapy in esophageal cancer. Lasers Med Sci. 2011; 26(1):69–78. Epub 2010/08/03. https://doi.org/10.1007/s10103-010-0810-0 PMID: 20676910.

34. White B, Rossi V, Baugher PJ. Aminolevulinic Acid-Mediated Photodynamic Therapy Causes Cell Death in MG-63 Human Osteosarcoma Cells. Photomed Laser Surg. 2016; 34(9):400–5. Epub 2016/08/09. https://doi.org/10.1089/pho.2016.4091 PMID: 27500317.

35. Rud E, Gederaas O, Øgset A, Berg K. 5-amino levulinic acid, but not 5-amino levulinic acid esters, is transported into adenocarcinoma cells by system BETA transporters. Photochem Photobiol. 2000; 71(5):640–7. Epub 2000/05/20. https://doi.org/10.1562/0031-8655(2000)071<0640:aabnaa>2.0.co;2 PMID: 10818796.

36. Itai Y, Ishii T, Kohda T, Ishizuka M, Yamazaki K, Nishimura Y, et al. Mechanistic study of PpIX accumulation using the JFCR39 cell panel revealed a role for dynamin 2-mediated exocytosis. Sci Rep. 2019; 9(1):8666. Epub 2019/06/19. https://doi.org/10.1038/s41598-019-44981-y PMID: 31209282; PubMed Central PMCID: PMC6572817 study was solely supported by the research and development budget of SBI Pharmaceuticals and was not sponsored by any other organizations.

37. Fujimoto S, Muguruma N, Okamoto K, Kurihara T, Sato Y, Miyamoto Y, et al. A Novel Theranostic Combination of Near-infrared Fluorescence Imaging and Laser Irradiation Targeting c-KIT for Gastrointestinal Stromal Tumors. Theranostics. 2018; 8(9):2313–28. Epub 2018/05/04. https://doi.org/10.7150/thno.22027 PMID: 29721082; PubMed Central PMCID: PMC5928892.

38. Tanaka M, Kataoka H, Yano S, Ohi H, Moriwaki K, Akashi H, et al. Antitumor effects in gastrointestinal stromal tumors using photodynamic therapy with a novel glucose-conjugated chlorin. Mol Cancer Ther. 2014; 13(4):767–75. Epub 2014/02/21. https://doi.org/10.1158/1535-7189.MCT-13-0393 PMID: 24552777.

39. Tanaka M, Kataoka H, Mabuchi M, Sakuma S, Takahashi S, Fujii R, et al. Anticancer effects of novel photodynamic therapy with glycoconjugated chlorin for gastric and colon cancer. Anticancer Res. 2011; 31(3):763–9. Epub 2011/04/19. PMID: 21498693.

40. Kaneko S, Kaneko S. Fluorescence-Guided Resection of Malignant Glioma with 5-ALA. Int J Biomed Imaging. 2016; 2016:6135293. Epub 2016/07/19. https://doi.org/10.1155/2016/6135293 PMID: 27429612; PubMed Central PMCID: PMC4939363.

41. Suzuki T, Wada S, Eguchi H, Adachi J, Mishima K, Matsutani M, et al. Cadherin 13 overexpression as an important factor related to the absence of tumor fluorescence in 5-aminolevulinic acid-guided resection of glioma. J Neurosurg. 2013; 119(5):1331–9. Epub 2013/09/10. https://doi.org/10.3171/2013.7.JN122340 PMID: 24010971.
42. Tipirneni KE, Rosenthal EL, Moore LS, Haskins AD, Udayakumar N, Jani AH, et al. Fluorescence Imaging for Cancer Screening and Surveillance. Mol Imaging Biol. 2017; 19(5):645–55. Epub 2017/02/06. https://doi.org/10.1007/s11307-017-1050-5 PMID: 28155079.

43. Gèze M, Morlière P, Mazière JC, Smith KM, Santos R. Lysosomes, a key target of hydrophobic photosensitizers proposed for photochemotherapeutic applications. J Photochem Photobiol B. 1993; 20(1):23–35. Epub 1993/09/01. https://doi.org/10.1016/1011-1344(93)80128-v PMID: 8229466.

44. Hamblin MR, Miller JL, Rizvi I, Ortel B, Maytin EV, Hasan T. Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer. Cancer Res. 2001; 61(19):7155–62. Epub 2001/10/05. PMID: 11585749.

45. Schwartz L, Supuran CT, Alfarouk KO. The Warburg Effect and the Hallmarks of Cancer. Anticancer Agents Med Chem. 2017; 17(2):164–70. Epub 2016/11/03. https://doi.org/10.2174/1871520616666161031134301 PMID: 27804847.

46. Namikawa T, Fujisawa K, Munekage E, Iwabu J, Uemura S, Tsujii S, et al. Clinical application of photodynamic medicine technology using light-emitting fluorescence imaging based on a specialized luminous source. Med Mol Morphol. 2018; 51(4):187–93. Epub 2018/04/06. https://doi.org/10.1007/s00795-018-0190-2 PMID: 29619546.

47. Inoue K, Fukushima H, Shimamoto T, Kamada M, Iiyama T, Miyamura M, et al. Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer. Cancer. 2012; 118(4):1062–74. Epub 2011/07/21. https://doi.org/10.1002/cncr.26378 PMID: 21773973.

48. Nishie H, Kataoka H, Yano S, Kikuchi JI, Hayashi N, Narumi A, et al. A next-generation bifunctional photosensitizer with improved water-solubility for photodynamic therapy and diagnosis. Oncotarget. 2016; 7(45):74259–68. Epub 2016/10/07. https://doi.org/10.18632/oncotarget.12366 PMID: 27708235; PubMed Central PMCID: PMC5342251.

49. Buytaert E, Callewaert G, Hendrickx N, Scorrano L, Hartmann D, Missiaen L, et al. Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy. Faseb J. 2006; 20(6):756–8. Epub 2006/02/04. https://doi.org/10.1096/fj.05-4305fje PMID: 16455754.

50. Ali-Seyed M, Bhuvaneswari R, Soo KC, Olivo M. Photolon™—photosensitization induces apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes. Int J Oncol. 2011; 39(4):821–31. Epub 2011/07/05. https://doi.org/10.3892/ijo.2011.1109 PMID: 21725591.

51. Li PX, Mu JH, Xiao HL, Li DH. Antitumor effect of photodynamic therapy with a novel targeted photosensitizer on cervical carcinoma. Oncol Rep. 2015; 33(1):125–32. Epub 2014/11/08. https://doi.org/10.3892/or.2014.3593 PMID: 25376180.

52. Chen JY, Cheung NH, Fung MC, Wen JM, Leung WN, Mak NK. Subcellular localization of merocyanine 540 (MC540) and induction of apoptosis in murine myeloid leukemia cells. Photochem Photobiol. 2000; 72(1):114–20. Epub 2000/07/27. https://doi.org/10.1562/0031-8655(2000)072<0114:sloma>2.0.co;2 PMID: 10911735.

53. Kushibiki T, Noji T, Ebihara Y, Hontani K, Ono M, Kuwabara S, et al. 5-Aminolevulinic-acid-mediated Photodynamic Diagnosis Enhances the Detection of Peritoneal Metastases in Biliary Tract Cancer in Mice. In Vivo. 2017; 31(5):905–8. Epub 2017/09/09. https://doi.org/10.21873/invivo.11145 PMID: 28882957; PubMed Central PMCID: PMC5656864.

54. Nakamura M, Nishikawa J, Hamabe K, Goto A, Nishimura J, Shibata H, et al. Preliminary study of photodynamic diagnosis using 5-aminolevulinic acid in gastric and colorectal tumors. World J Gastroenterol. 2015; 21(21):6706–12. Epub 2015/06/16. https://doi.org/10.3748/wjg.v21.i21.6706 PMID: 26074709; PubMed Central PMCID: PMC4458781.

55. Kawai N, Hirohashi Y, Ebihara Y, Saito T, Murai A, Saito T, et al. ABCG2 expression is related to low 5-ALA photodynamic diagnosis (PDD) efficacy and cancer stem cell phenotype, and suppression of ABCG2 improves the efficacy of PDD. PLoS One. 2019; 14(5):e0216503. Epub 2019/05/15. https://doi.org/10.1371/journal.pone.0216503 PMID: 31083682; PubMed Central PMCID: PMC6513434.